TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31313068

Group type: EXPERIMENTAL
Intervention: Bortezomib at an intravenous dose of 1.3 mg/m2 twice weekly
Number of subjects: 28
Study: 29302744

Group type: EXPERIMENTAL
Intervention: Situs inversus totalis (SIT) participants
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Situs inversus totalis (SIT) participants with primary ciliary dyskinesia (PCD)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Situs inversus totalis (SIT) participants without primary ciliary dyskinesia (PCD)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 15
Study: 27919632

Group type: EXPERIMENTAL
Intervention: MF59‐adjuvanted trivalent inactivated influenza vaccine (MF59‐aTIV) + 13‐valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: PCV13 alone
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: MF59‐aTIV alone
Number of subjects: 1149

Group type: EXPERIMENTAL
Intervention: Concomitant administration of MF59‐aTIV and PCV13
Number of subjects: 1149
Study: 25099523

Group type: EXPERIMENTAL
Intervention: Pregabalin (75 mg twice-weekly)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Ondansetron (8 mg/day)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 24107437

Group type: EXPERIMENTAL
Intervention: Intravenous zoledronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral ibandronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study: 22105251

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 0.25% ropivacaine
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 75
Study: 18192897

Group type: EXPERIMENTAL
Intervention: Simvastatin (80 mg/day)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg/day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: E. coli lipopolysaccharide (LPS) infusion
Number of subjects: 6
Study: 16729930

Group type: EXPERIMENTAL
Intervention: Atorvastatin, 80 mg daily
Number of subjects: 9000

Group type: COMPARATOR
Intervention: Simvastatin, 20 or 40 mg daily
Number of subjects: 9000
Study: 14515285

Group type: EXPERIMENTAL
Intervention: Peritoneal mesothelial cells
Number of subjects: 0
Study: 11050702

Group type: EXPERIMENTAL
Intervention: Cibalginadue Fast (test formulation)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference formulation (tablets)
Number of subjects: 18
Study: 8792796

Group type: EXPERIMENTAL
Intervention: In-patient multidisciplinary rehabilitation program (21 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Out-patient physiotherapy designed by the patient's rheumatologist
Number of subjects: 26
Study: 1613682

Group type: EXPERIMENTAL
Intervention: Midazolam anaesthesia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Thiopental anaesthesia
Number of subjects: 12
Study: 6486124

Group type: EXPERIMENTAL
Intervention: Nifedipine 40 mg daily
Number of subjects: 122

Group type: COMPARATOR
Intervention: Hydralazine 86 mg daily
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 to 90 mg)
Number of subjects: 122
Study: 31994006

Group type: EXPERIMENTAL
Intervention: Peer mentor intervention for 12 weeks
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Peer mentor intervention
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Recruitment via social media
Number of subjects: 48
Study: 29940668

Group type: EXPERIMENTAL
Intervention: HPβCD/Ang‐(1‐7)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HPβCD (Placebo)
Number of subjects: 0
Study: 26542812

Group type: EXPERIMENTAL
Intervention: 0.5 mg sublingual testosterone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 24176251

Group type: EXPERIMENTAL
Intervention: Immediate start of the contraceptive patch (directly observed application of the patch in the clinic)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Delayed start of the contraceptive patch (beginning the Sunday after their abortion)
Number of subjects: 298
Study: 23562564

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3D-CRT)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: IMRT
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Both IMRT and 3D-CRT
Number of subjects: 58

Group type: COMPARATOR
Intervention: 3D-CRT
Number of subjects: 58
Study: 21043553

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (Lysteda)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18238972

Group type: EXPERIMENTAL
Intervention: Cessation medication discussion with obstetric providers
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Nicotine replacement
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Medication use during pregnancy
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Medication discussion at postpartum visit
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Medication use postpartum
Number of subjects: 296

Group type: EXPERIMENTAL
Intervention: Factors associated with medication use
Number of subjects: 296
Study: 16325968

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFA supplementation (390-1170 mg/day)
Number of subjects: 17
Study: 12755236

Group type: EXPERIMENTAL
Intervention: Daily supplementation (60 mg elemental iron, 300 mg ferrous sulphate, 400 microg folic acid, Monday to Friday)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Weekly supplementation (one tablet once a week every Monday)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group (no medications)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Daily supplementation
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Weekly supplementation
Number of subjects: 207
Study: 10939035

Group type: EXPERIMENTAL
Intervention: Theophylline (Respicur retard 400 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9174209

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 14-(R)-hydroxyclarithromycin
Number of subjects: 40
Study: 8251272

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tracheal Intubation
Number of subjects: 20
Study: 3080101

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional insulin injection therapy (controls)
Number of subjects: 12
Study: 29966499

Group type: EXPERIMENTAL
Intervention: Culturally Adapted Behavioral Family Psycho‐Education Program (CA-BFPEP), 14 sessions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 60
Study: 26244828

Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (WBVT) for 5 weeks
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (identical exercises without vibration)
Number of subjects: 2
Study: 24651243

Group type: EXPERIMENTAL
Intervention: Medial cord stimulation with 40 mL of 0.5% ropivacaine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Posterior cord stimulation with 40 mL of 0.5% ropivacaine
Number of subjects: 96
Study: 21673624

Group type: EXPERIMENTAL
Intervention: Jadad assessment tool
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: van Tulder assessment tool
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Risk of Bias (RoB) assessment tool
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Jadad assessment tool for allocation concealment
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: van Tulder assessment tool for allocation concealment
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Risk of Bias (RoB) for allocation concealment
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: van Tulder assessment tool for sequence generation
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Risk of Bias (RoB) for sequence generation
Number of subjects: 54
Study: 20685858

Group type: EXPERIMENTAL
Intervention: 20 μg alum-formulated human recombinant GAD65
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 73
Study: 18018993

Group type: EXPERIMENTAL
Intervention: Self-care + 6 x 6 exercises
Number of subjects: 45

Group type: COMPARATOR
Intervention: Self-care
Number of subjects: 45
Study: 16142556

Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tension free vaginal tape (TVT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: TVT
Number of subjects: 50
Study: 11161417

Group type: EXPERIMENTAL
Intervention: Hypothesis-testing training tasks
Number of subjects: 5

Group type: COMPARATOR
Intervention: Memorization training tasks
Number of subjects: 5
Study: 9008243

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Measurements-only control group
Number of subjects: 0
Study: 7984577

Group type: EXPERIMENTAL
Intervention: Carriers of antigen HLA-DR2 and haptoglobin phenotype 2-2
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Combination of HLA-DR2 and haptoglobin phenotype 2-2
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Carriers of HLA-DR2 and haptoglobin phenotype 2-2
Number of subjects: 84
Study: 3549757

Group type: EXPERIMENTAL
Intervention: Patient education
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Physician education
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Both patient and physician education
Number of subjects: 532

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 532
Study: 29285955

Group type: EXPERIMENTAL
Intervention: TIGRIS stent
Number of subjects: 274

Group type: COMPARATOR
Intervention: LifeStent
Number of subjects: 274
Study: 27102382

Group type: EXPERIMENTAL
Intervention: Bioactive stents (BAS)
Number of subjects: 827

Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 827
Study: 24034658

Group type: EXPERIMENTAL
Intervention: Automated telephone call advising to have a walk-in BP check
Number of subjects: 64773

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64773
Study: 21699720

Group type: EXPERIMENTAL
Intervention: Hibler's method
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ambulance blankets / quilts
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bubble wrap
Number of subjects: 8
Study: 18714107

Group type: EXPERIMENTAL
Intervention: Factor VIIa (recombinant)
Number of subjects: 0
Study: 17060001

Group type: EXPERIMENTAL
Intervention: Coiled catheter
Number of subjects: 132

Group type: COMPARATOR
Intervention: Straight catheter
Number of subjects: 132
Study: 12947433

Group type: EXPERIMENTAL
Intervention: Fish oil (4 x 1 g) containing a natural carotenoid mixture (4 x 7.6 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Fish oil (4 x 1 g)
Number of subjects: 32
Study: 10702522

Group type: EXPERIMENTAL
Intervention: Storage at -70 degrees C
Number of subjects: 0
Study: 9051365

Group type: COMPARATOR
Intervention: Conventional subcutaneous injection technique (with skin preparation)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Experimental injection technique through clothing
Number of subjects: 50
Study: 8398919

Group type: EXPERIMENTAL
Intervention: Longer radiotherapy treatment schedule
Number of subjects: 63

Group type: COMPARATOR
Intervention: Shorter radiotherapy treatment schedule
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Trait anxiety
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Coping style
Number of subjects: 63
Study: 3137773

Group type: EXPERIMENTAL
Intervention: Low-dose disodium etidronate (EHDP) 5-7 mg/kg/day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Low-dose disodium etidronate (EHDP) plus 1 alpha-hydroxyvitamin D3 (1 alpha D3) 0.5 mcg daily
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 29672085

Group type: EXPERIMENTAL
Intervention: 8-week REACH Forgiveness intervention
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: 8-week process group
Number of subjects: 162

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 162
Study: 27025451

Group type: EXPERIMENTAL
Intervention: Active stretch group (Bartenieff Fundamentals(TM) thigh lift)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Passive stretch group (contract‐release‐contract form of PNF)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study: 23616267

Group type: EXPERIMENTAL
Intervention: Patient-specific guides (PSGs)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Conventional instrumentation
Number of subjects: 128
Study: 23362285

Group type: EXPERIMENTAL
Intervention: Early ART initiation (within 7 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Delayed ART initiation (after 28 days)
Number of subjects: 27
Study: 20033338

Group type: EXPERIMENTAL
Intervention: Limited hiatal dissection combined with myotomy and Dor's procedure (G2)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Heller's myotomy alone (G3)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Complete hiatal dissection (G1)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Postoperative dysphagia recurrence
Number of subjects: 84
Study: 17701189

Group type: EXPERIMENTAL
Intervention: XCaliber pins (Orthofix)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard pins (Orthofix)
Number of subjects: 50
Study: 21419560

Group type: EXPERIMENTAL
Intervention: Mechanical chest compressions using the LUCAS™ device
Number of subjects: 149

Group type: COMPARATOR
Intervention: Manual chest compressions
Number of subjects: 149
Study: 16272188

Group type: EXPERIMENTAL
Intervention: Modafinil 200mg/day
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Modafinil 400mg/day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 12016099

Group type: EXPERIMENTAL
Intervention: Flunisolide-CFC
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Triamcinolone-CFC
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Beclomethasone-CFC
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Fluticasone DPI
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Budesonide DPI
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Fluticasone-CFC MDI
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study: 10085995

Group type: EXPERIMENTAL
Intervention: Reciprocal, multimodal (ATVV) stimulation paired with line singing of Brahms' Lullaby, provided for 15‐30 minutes, one or two times per week from referral to discharge.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Reciprocal, multimodal (ATVV) stimulation paired with line singing of Brahms' Lullaby.
Number of subjects: 40
Study: 8067594

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3339718

Group type: EXPERIMENTAL
Intervention: Potassium citrate (80 mEq. per day)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sodium citrate (80 mEq. per day)
Number of subjects: 6
Study: 28885392

Group type: EXPERIMENTAL
Intervention: External thermomechanical stimulation using Buzzy
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Distraction via DistrACTION Cards
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Combination of external thermomechanical stimulation and distraction
Number of subjects: 218

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 218
Study: 29471927

Group type: EXPERIMENTAL
Intervention: Live supervision using Teleconferencing
Number of subjects: 97

Group type: COMPARATOR
Intervention: Tape-based supervision
Number of subjects: 97

Group type: COMPARATOR
Intervention: Workshop only
Number of subjects: 97
Study: 26979712

Group type: EXPERIMENTAL
Intervention: Coffee consumption (four 200 ml coffee beverages containing 160 mg caffeine)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 40
Study: 25572571

Group type: EXPERIMENTAL
Intervention: S-1 plus cisplatin with concurrent thoracic radiation (SCCR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cisplatin alone with concurrent thoracic radiation (CCR)
Number of subjects: 40
Study: 23702705

Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Epidural block (EP)
Number of subjects: 70
Study: 20339174

Group type: EXPERIMENTAL
Intervention: Pylorus preserving pancreaticoduodenectomy (PPPD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classic pancreaticoduodenectomy (PD)
Number of subjects: 0
Study: 18821628

Group type: EXPERIMENTAL
Intervention: 0.5% midazolam formulation (MDG) - 1.0 mg total dose, intranasally into each nostril
Number of subjects: 108

Group type: COMPARATOR
Intervention: 1% midazolam formulation (UDG) - 1.0 mg total dose, intranasally into one nostril
Number of subjects: 108

Group type: COMPARATOR
Intervention: 1% midazolam formulation (UDG)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 0.5% midazolam formulation (MDG)
Number of subjects: 108
Study: 16610379

Group type: EXPERIMENTAL
Intervention: Waterproof cast liner
Number of subjects: 59

Group type: COMPARATOR
Intervention: Cotton cast liner
Number of subjects: 59
Study: 12801285

Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite + EDTA
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 2.5% sodium hypochlorite
Number of subjects: 36

Group type: COMPARATOR
Intervention: 2% chlorhexidine
Number of subjects: 36

Group type: COMPARATOR
Intervention: saline
Number of subjects: 36
Study: 10817583

Group type: EXPERIMENTAL
Intervention: Presence of depression predicted by superior frontal and superior parietal hypointense TI lesions
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Severity of depression predicted by superior frontal, superior parietal and temporal TI lesions, lateral and third ventricular enlargement, and frontal atrophy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: EDSS weakly predictive of presence of depression
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: EDSS weakly predictive of severity of depression
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Depression not related to bright T2 lesions or enhancement
Number of subjects: 48
Study: 8899495

Group type: EXPERIMENTAL
Intervention: Short-course triple therapy (bismuth subsalicylate two tablets four times daily, amoxicillin 1 g twice daily, metronidazole 500 mg four times daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: High-dose omeprazole (40 mg twice a day) with amoxicillin (1 g twice a day)
Number of subjects: 34
Study: 1665778

Group type: EXPERIMENTAL
Intervention: Naloxone (0.75 mg/70 kg i.m.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Methadone (30 mg i.m.)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Naloxone challenge at 24 h post-methadone
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 6
Study: 6881268

Group type: EXPERIMENTAL
Intervention: Silcon contact lenses
Number of subjects: 10

Group type: COMPARATOR
Intervention: Polycon II contact lenses
Number of subjects: 10
Study: 30595323

Group type: EXPERIMENTAL
Intervention: Daily regimen (DR) atorvastatin therapy (10 mg for 12 weeks)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Every other day regimen (EODR) atorvastatin therapy (10 mg for 12 weeks)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Daily regimen (DR) atorvastatin therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Every other day regimen (EODR) atorvastatin therapy
Number of subjects: 61
Study: 27448477

Group type: EXPERIMENTAL
Intervention: Reading from an iPad
Number of subjects: 16

Group type: COMPARATOR
Intervention: Reading from a book
Number of subjects: 16
Study: 25039318

Group type: EXPERIMENTAL
Intervention: Anakinra (150 mg daily for 4 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 22674920

Group type: EXPERIMENTAL
Intervention: Booklet based vestibular rehabilitation with telephone support
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Booklet based vestibular rehabilitation only
Number of subjects: 337

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 337
Study: 20728505

Group type: EXPERIMENTAL
Intervention: Fuji II LC (GC) applied on bur-cut dentin with polyalkenoic-acid conditioner
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fuji II LC (GC) applied on bur-cut dentin without polyalkenoic-acid conditioner
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fuji II LC (GC) applied on fractured dentin with or without conditioner
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fuji II LC (GC) applied on laser-irradiated dentin with or without conditioner
Number of subjects: 48
Study: 18755999

Group type: EXPERIMENTAL
Intervention: Topic links
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nonspecific links
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 15755829

Group type: EXPERIMENTAL
Intervention: High protein intake (HP) - 5 g . kg(‐1) . d(‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intermediate protein intake (IP) - 3 g . kg(‐1) . d(‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Normal protein intake (NP) - 1.5 g . kg(‐1) . d(‐1)
Number of subjects: 8
Study: 14749241

Group type: EXPERIMENTAL
Intervention: Isoflavone supplement (26 mg biochanin A, 16 mg formononetin, 1 mg genistein, 0.5 mg daidzein for 1 year)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Isoflavone supplement
Number of subjects: 205

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 205
Study: 11532845

Group type: EXPERIMENTAL
Intervention: Interactive multimedia decision aid
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 112
Study: 9280173

Group type: EXPERIMENTAL
Intervention: Diet plus strength training
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Diet plus aerobic training
Number of subjects: 65

Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 65